THE PASSION TO PURSUE MORE
Who we are
Actuate aims to give patients with hard-to-treat cancers the opportunity to live longer and better through a best-in-class agent with the potential capacity to slow, stop, or shrink tumors, with minimal adverse effects.
Actuate’s lead drug, elraglusib (a novel GSK-3 inhibitor), targets multiple molecular pathways in cancer that are involved in promoting tumor growth and resistance to conventional cancer drugs such as chemotherapy. Elraglusib is also emerging as a mediator of anti-tumor immunity through the inhibition of multiple immune checkpoints and the regulation of immune cell function.
Learn more about the science that drives our novel agent, elraglusib.
Learn more about what therapies and potential indications are on the horizon.